

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/510,677
(Use as many sheets as necessary)				Filing Date	2003-04-09
				First Named Inventor	M. Parrington
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	1	of	1	Attorney Docket No: API-01-20-US	

US PATENT DOCUMENTS

Examiner Initials *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A94	4,923,808	1990-05-08	Matteucci, et al.	Entire document
	A95	6,407,063	2002-06-18	Luitjen, et al.	Entire document

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	B10	WO 98/29556A1	1998-07-09	The Wistar Institute	Entire document	
	B11	WO 99/46992A1	1999-09-23	Genzyme Corporation	Entire document	
	B12	WO 99/46988	1998-03-20	Genzyme Corporation	Entire document	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C28	BERINSTEIN, et al. Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review. <i>J. Clin. Oncol.</i> 20(8): 2197-2207 (2002)	
	C29	DUBENSKY, et al. Delivery Systems for Gene-Based Vaccines. <i>Mol. Med.</i> 6(9): 723-732 (2000)	
	C30	HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. <i>Vaccine</i> , vol. 15, issue 6/7, pp. 759-768 (1997)	
	C31	LEITNER, et al. Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors. <i>Cancer Res.</i> 60: 51-55 (2000)	
	C32	MARSHALL, J. Carcinoembryonic Antigen-Based Vaccines. <i>Semin. Oncol.</i> (suppl. 8): 30-36 (2003)	
	C33	PARDOLL, D.M. Cancer vaccines. <i>Nat. Med.</i> 4: 525-531 (1998)	
	C34	PARMIANI, et al. Cancer Immunotherapy with Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? <i>J. Natl. Cancer Inst.</i> 94: 805-818 (2002)	
	C36	VAN DER BURG, et al. Induction of p53-Specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine. <i>Clin. Cancer Res.</i> 8: 1019-1027 (2002)	

EXAMINER

DATE CONSIDERED